How to Buy Krystal Biotech Stock
Krystal Biotech Inc
Krystal Biotech, Inc. , a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.
Krystal Biotech stock last closed at $161.91, down 3.95% from the previous day, and has increased 2.96% in one year. It has overperformed other stocks in the Biotechnology industry by 0.81 percentage points. Krystal Biotech stock is currently +14.25% from its 52-week low of $141.72, and -26.18% from its 52-week high of $219.34.
As of Apr 21, 2025, there are 28.81M KRYS shares outstanding. The market capitalization of KRYS is $4.66B. In the past 24 hours, 291,385 KRYS shares were traded.
How to Buy Krystal Biotech Stock
Not sure how to invest in Krystal Biotech stock? Here's how.
- Choose where to buy Krystal Biotech stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you decide where to buy Krystal Biotech stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Pick your payment method and add your info.
- Analyze Krystal Biotech stock: The Krystal Biotech ticker symbol is KRYS. Is Krystal Biotech stock a good investment? Should you buy shares of KRYS? How do KRYS's underlying business fundamentals look? Do top analysts think Krystal Biotech is a good buy? Why has KRYS's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if KRYS is a good stock to buy).
- Execute your KRYS buy order: Decide if you will purchase KRYS shares at the current market price or use a limit order to purchase KRYS stock at a specific price.
- Get updates on your KRYS investment: Create a watchlist to keep tabs on your new investment in Krystal Biotech shares.
Step 1: Choose where to buy Krystal Biotech stock
You need an online brokerage account in order to access the NASDAQ market and buy KRYS stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Tech to Utilities, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the best brokerage, you need to fill out some personal info so you are able to buy KRYS today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start your new brokerage account.
- Submit your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have opened your account on one of the best stock market apps, your next step is to transfer the money for your investment:
Watch the tutorial below for more details transferring funds into your brokerage account.
Step 4: Analyze Krystal Biotech stock
Once you have selected the best place to buy Krystal Biotech stock, it's important to evaluate their stock before you buy, so you truly understand the risk and upside.
Krystal Biotech stock data
KRYS Due Diligence Checks
WallStreetZen was created to help part-time investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on KRYS's stock page.
How is KRYS stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge KRYS's intrinsic value.
Using relative valuations methods:
- KRYS could be undervalued based on its P/E ratio of 51.89x, relative to Biotechnology industry P/E ratio of -184.27x
- KRYS may be overvalued based on its P/B ratio of 4.93x, relative to Biotechnology industry P/B ratio of 4.04x
- KRYS could be undervalued based on its PEG ratio of 0.85x
You can access additional valuation analysis on KRYS's stock here.
How do KRYS Financials look?
Passed Health Checks:
- KRYS has a low debt to equity ratio of 0.12.
- There are more short-term assets than long-term liabilities on the KRYS balance sheet.
- KRYS earnings of $95.36M is not sufficient to cover its interest payments.
- KRYS's operating cash flow of $123.42M allows it to safely service it's debt of $7.26M.
- There are more short-term assets than short-term liabilities on the KRYS balance sheet.
- KRYS profit margin has gone up from 21.6% to 30.7% in the past year.
Failed Health Checks:
- Total KRYS debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy KRYS stock, according to Wall Street analysts?
Out of 5 Equities analysts who research KRYS, the consensus analyst rating on KRYS is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Krystal Biotech stock forecast page.
KRYS Momentum
KRYS Performance Numbers
Last year, KRYS earnings were $89.16M. In the past one years, KRYS's earnings have gone up by 680% per year. This was faster than the Biotechnology industry average of 10.61%.
Last year, KRYS revenue was $290.52M. Over the last 1 years, KRYS's revenue has grown by 473.02% per year. This was faster than the Biotechnology industry average of 44.31%.
You can analyze KRYS's earnings and revenue performance here.
Who is buying/selling KRYS?
Over the last 12 months, executives and large shareholders at KRYS have sold more shares than they have bought.
Krish S. Krishnan, President and CEO of KRYS, was the latest KRYS insider to sell. They sold $193,408.60 worth of KRYS shares on Mar 13, 2025.
Get more info about who owns KRYS stock here.
Does KRYS provide a stable income stream?
No, Krystal Biotech doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your KRYS buy order
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular price, place a limit order.
Hit the Open Trade button and eToro will place your order.
If you require additional help investing in stocks on eToro, click the helpful video below:
Step 6: Get updates on your KRYS investment
Now that you own some KRYS stock, you'll want to keep up with your new stock purchase.
Create a watchlist to get the latest updates about your KRYS stock.
KRYS Feed
How to Buy Stock in Krystal Biotech
To reiterate, here are the 6 steps for buying Krystal Biotech stock:
- Choose where to buy Krystal Biotech stock
- Create your brokerage account
- Deposit funds into your investment account
- Analyze Krystal Biotech stock
- Execute your KRYS buy order
- Get updates on your KRYS investment
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest news on your investment in Krystal Biotech, click below.
More Stock Buying Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.